ID   SCM1_MESMA              Reviewed;          84 AA.
AC   P45697;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 2.
DT   07-APR-2021, entry version 120.
DE   RecName: Full=Alpha-like toxin BmK M1 {ECO:0000303|PubMed:10089445, ECO:0000303|PubMed:10493862, ECO:0000303|PubMed:11322948, ECO:0000303|PubMed:12692120, ECO:0000303|PubMed:12705833, ECO:0000303|PubMed:15321715, ECO:0000303|PubMed:9248001};
DE            Short=BmK-M1;
DE            Short=BmKM1;
DE   AltName: Full=BmK-I;
DE            Short=BmK I {ECO:0000303|PubMed:14554105, ECO:0000303|PubMed:16229835, ECO:0000303|PubMed:19162162, ECO:0000303|PubMed:20678086, ECO:0000303|PubMed:8896191};
DE            Short=BmKI;
DE   AltName: Full=BmK1;
DE   Flags: Precursor;
OS   Mesobuthus martensii (Manchurian scorpion) (Buthus martensii).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Chelicerata; Arachnida;
OC   Scorpiones; Buthida; Buthoidea; Buthidae; Mesobuthus.
OX   NCBI_TaxID=34649;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Venom gland;
RX   PubMed=9248001; DOI=10.1016/s0041-0101(96)00224-3;
RA   Xiong Y.-M., Ling M.-H., Wang D.-C., Chi C.-W.;
RT   "The cDNA and genomic DNA sequences of a mammalian neurotoxin from the
RT   scorpion Buthus martensii Karsch.";
RL   Toxicon 35:1025-1031(1997).
RN   [2]
RP   PROTEIN SEQUENCE OF 20-83, FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Venom;
RX   PubMed=8896191; DOI=10.1016/0041-0101(96)00065-7;
RA   Ji Y.-H., Mansuelle P., Terakawa S., Kopeyan C., Yanaihara N., Hsu K.,
RA   Rochat H.;
RT   "Two neurotoxins (BmK I and BmK II) from the venom of the scorpion Buthus
RT   martensi Karsch: purification, amino acid sequences and assessment of
RT   specific activity.";
RL   Toxicon 34:987-1001(1996).
RN   [3]
RP   FUNCTION, AND FUNCTION ON SCN5A SODIUM CHANNELS.
RX   PubMed=11322948; DOI=10.1016/s0014-5793(01)02365-1;
RA   Goudet C., Huys I., Clynen E., Schoofs L., Wang D.C., Waelkens E.,
RA   Tytgat J.;
RT   "Electrophysiological characterization of BmK M1, an alpha-like toxin from
RT   Buthus martensi Karsch venom.";
RL   FEBS Lett. 495:61-65(2001).
RN   [4]
RP   MUTAGENESIS OF TYR-24; LYS-27; PRO-28; HIS-29; ASN-30; TYR-40; LYS-47;
RP   ASP-72; ARG-77; LYS-81 AND HIS-83, FUNCTION ON SCN2A AND SCN4A SODIUM
RP   CHANNELS, AND TOXIC DOSE.
RX   PubMed=12705833; DOI=10.1021/bi0270438;
RA   Wang C.-G., Gilles N., Hamon A., Le Gall F., Stankiewicz M., Pelhate M.,
RA   Xiong Y.-M., Wang D.-C., Chi C.-W.;
RT   "Exploration of the functional site of a scorpion alpha-like toxin by site-
RT   directed mutagenesis.";
RL   Biochemistry 42:4699-4708(2003).
RN   [5]
RP   MUTAGENESIS OF TYR-24; TRP-57 AND TYR-61.
RX   PubMed=12692120; DOI=10.1074/jbc.m211931200;
RA   Sun Y.-M., Bosmans F., Zhu R.-H., Goudet C., Xiong Y.-M., Tytgat J.,
RA   Wang D.-C.;
RT   "Importance of the conserved aromatic residues in the scorpion alpha-like
RT   toxin BmK M1: the hydrophobic surface region revisited.";
RL   J. Biol. Chem. 278:24125-24131(2003).
RN   [6]
RP   FUNCTION, AND BIOASSAY.
RX   PubMed=14554105; DOI=10.1016/s0041-008x(03)00260-6;
RA   Bai Z.T., Zhang X.Y., Ji Y.H.;
RT   "Fos expression in rat spinal cord induced by peripheral injection of BmK
RT   I, an alpha-like scorpion neurotoxin.";
RL   Toxicol. Appl. Pharmacol. 192:78-85(2003).
RN   [7]
RP   FUNCTION, TOXIC DOSE, AND MUTAGENESIS OF VAL-20; ARG-21; ASP-22; ILE-25;
RP   PRO-28; HIS-29; GLY-53; GLY-62; LEU-70; PRO-71; ILE-76; VAL-78; PRO-79 AND
RP   GLY-80.
RX   PubMed=15677695;
RA   Liu L.-H., Bosmans F., Maertens C., Zhu R.-H., Wang D.-C., Tytgat J.;
RT   "Molecular basis of the mammalian potency of the scorpion alpha-like toxin,
RT   BmK M1.";
RL   FASEB J. 19:594-596(2005).
RN   [8]
RP   FUNCTION, AND BIOASSAY.
RX   PubMed=16229835; DOI=10.1016/j.expneurol.2005.09.006;
RA   Bai Z.T., Zhao R., Zhang X.Y., Chen J., Liu T., Ji Y.H.;
RT   "The epileptic seizures induced by BmK I, a modulator of sodium channels.";
RL   Exp. Neurol. 197:167-176(2006).
RN   [9]
RP   FUNCTION.
RX   PubMed=19162162; DOI=10.1016/j.tiv.2008.12.022;
RA   Zhu M.M., Tan M., Cheng H.W., Ji Y.H.;
RT   "The alpha-like scorpion toxin BmK I enhances membrane excitability via
RT   persistent sodium current by preventing slow inactivation and deactivation
RT   of rNav1.2a expressed in Xenopus oocytes.";
RL   Toxicol. in Vitro 23:561-568(2009).
RN   [10]
RP   FUNCTION.
RC   TISSUE=Venom;
RX   PubMed=20678086; DOI=10.1042/bj20100517;
RA   He H., Liu Z., Dong B., Zhou J., Zhu H., Ji Y.;
RT   "Molecular determination of selectivity of the site 3 modulator (BmK I) to
RT   sodium channels in the CNS: a clue to the importance of Nav1.6 in BmK I-
RT   induced neuronal hyperexcitability.";
RL   Biochem. J. 431:289-298(2010).
RN   [11]
RP   CRYSTALLIZATION.
RC   TISSUE=Venom;
RX   PubMed=10089445; DOI=10.1107/s0907444998006593;
RA   Li H.-M., Zhao T., Jin L., Wang M., Zhang Y., Wang D.-C.;
RT   "A series of bioactivity-variant neurotoxins from scorpion Buthus martensii
RT   Karsch: purification, crystallization and crystallographic analysis.";
RL   Acta Crystallogr. D 55:341-344(1999).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 20-83.
RX   PubMed=10493862; DOI=10.1006/jmbi.1999.3036;
RA   He X.-L., Li H.-M., Zeng Z.-H., Liu X.-Q., Wang M., Wang D.-C.;
RT   "Crystal structures of two alpha-like scorpion toxins: non-proline cis
RT   peptide bonds and implications for new binding site selectivity on the
RT   sodium channel.";
RL   J. Mol. Biol. 292:125-135(1999).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 19-83, AND MUTAGENESIS OF LYS-27
RP   AND PRO-28.
RX   PubMed=15321715; DOI=10.1016/j.jmb.2004.06.067;
RA   Guan R.-J., Xiang Y., He X.-L., Wang C.-G., Wang M., Zhang Y.,
RA   Sundberg E.J., Wang D.-C.;
RT   "Structural mechanism governing cis and trans isomeric states and an
RT   intramolecular switch for cis/trans isomerization of a non-proline peptide
RT   bond observed in crystal structures of scorpion toxins.";
RL   J. Mol. Biol. 341:1189-1204(2004).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 19-83, AND MUTAGENESIS.
RX   PubMed=16209876; DOI=10.1016/j.jmb.2005.08.068;
RA   Ye X., Bosmans F., Li C., Zhang Y., Wang D.-C., Tytgat J.;
RT   "Structural basis for the voltage-gated Na+ channel selectivity of the
RT   scorpion alpha-like toxin BmK M1.";
RL   J. Mol. Biol. 353:788-803(2005).
CC   -!- FUNCTION: Alpha toxins bind voltage-independently at site-3 of sodium
CC       channels (Nav) and inhibit the inactivation of the activated channels
CC       thereby blocking neuronal transmission. This toxin is active against
CC       both mammals and insects, and is classified as an alpha-like toxin. It
CC       is active on Nav1.2/SCN2A (EC(50)=139-252 nM), Nav1.3/SCN3A (EC(50)=565
CC       nM), Nav1.4/SCN4A and Nav1.5/SCN5A (EC(50)=195-500 nM), Nav1.6/SCN8A
CC       (EC(50)=214 nM), and drosophila DmNav1 (EC(50)=30 nM) (PubMed:11322948,
CC       PubMed:12705833, PubMed:15677695, PubMed:19162162, PubMed:20678086). In
CC       mNav1.6/SCN8A, the toxin induces a large increase in both transient and
CC       persistent currents, which correlates with a prominent reduction in the
CC       fast component of inactivating current (PubMed:20678086). In
CC       rNav1.2/SCN2A and rNav1.3/SCN3A, toxin-increased currents is much
CC       smaller (PubMed:19162162, PubMed:20678086). Moreover, the toxin only
CC       accelerates the slow inactivation development and delay recovery of
CC       mNav1.6/SCN8A through binding to the channel in the open state
CC       (PubMed:20678086). Is 6-fold more toxic than BmK-M2. In vivo,
CC       intrahippocampal injection into rat induces epileptiform responses
CC       (PubMed:16229835). In addition, intraplantar injection into rat induces
CC       spontaneous nociception and hyperalgesia (PubMed:14554105).
CC       {ECO:0000269|PubMed:11322948, ECO:0000269|PubMed:12705833,
CC       ECO:0000269|PubMed:14554105, ECO:0000269|PubMed:15677695,
CC       ECO:0000269|PubMed:16229835, ECO:0000269|PubMed:19162162,
CC       ECO:0000269|PubMed:20678086}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:8896191}.
CC   -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC       {ECO:0000305|PubMed:8896191}.
CC   -!- DOMAIN: Has the structural arrangement of an alpha-helix connected to
CC       antiparallel beta-sheets by disulfide bonds (CS-alpha/beta).
CC       {ECO:0000269|PubMed:10493862, ECO:0000269|PubMed:15321715,
CC       ECO:0000269|PubMed:16209876}.
CC   -!- TOXIC DOSE: LD(50) is 0.75 mg/kg by intravenous injection into mice.
CC       {ECO:0000269|PubMed:12705833}.
CC   -!- TOXIC DOSE: LD(50) is 0.53 mg/kg by intravenous injection into tail
CC       mice. {ECO:0000269|PubMed:12705833, ECO:0000269|PubMed:15677695}.
CC   -!- MISCELLANEOUS: Exists in two forms, due to cis-trans isomerization at
CC       28-Pro-His-29. {ECO:0000269|PubMed:15321715}.
CC   -!- MISCELLANEOUS: Has insignificant effect on Nav1.2/SCN2A.
CC       {ECO:0000269|PubMed:12705833, ECO:0000269|PubMed:15677695}.
CC   -!- SIMILARITY: Belongs to the long (4 C-C) scorpion toxin superfamily.
CC       Sodium channel inhibitor family. Alpha subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA69557.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF057554; AAC13693.1; -; Genomic_DNA.
DR   EMBL; U28659; AAA69557.1; ALT_INIT; mRNA.
DR   PDB; 1DJT; X-ray; 1.20 A; A/B=20-83.
DR   PDB; 1SN1; X-ray; 1.70 A; A=20-83.
DR   PDB; 1T7A; X-ray; 1.50 A; A=20-83.
DR   PDB; 1T7B; X-ray; 1.85 A; A=20-83.
DR   PDB; 1T7E; X-ray; 1.40 A; A=20-83.
DR   PDB; 1ZU3; X-ray; 1.33 A; A=20-83.
DR   PDB; 1ZUT; X-ray; 1.70 A; A=20-83.
DR   PDB; 1ZVE; X-ray; 1.70 A; A=20-83.
DR   PDB; 1ZVG; X-ray; 1.20 A; A=20-83.
DR   PDB; 1ZYV; X-ray; 1.50 A; A=20-83.
DR   PDB; 1ZYW; X-ray; 1.30 A; A=20-83.
DR   PDBsum; 1DJT; -.
DR   PDBsum; 1SN1; -.
DR   PDBsum; 1T7A; -.
DR   PDBsum; 1T7B; -.
DR   PDBsum; 1T7E; -.
DR   PDBsum; 1ZU3; -.
DR   PDBsum; 1ZUT; -.
DR   PDBsum; 1ZVE; -.
DR   PDBsum; 1ZVG; -.
DR   PDBsum; 1ZYV; -.
DR   PDBsum; 1ZYW; -.
DR   SMR; P45697; -.
DR   TCDB; 8.B.1.1.1; the long (4c-c) scorpion toxin (l-st) superfamily.
DR   EvolutionaryTrace; P45697; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0019871; F:sodium channel inhibitor activity; IEA:InterPro.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
DR   GO; GO:0006952; P:defense response; IEA:InterPro.
DR   GO; GO:0009405; P:pathogenesis; IEA:InterPro.
DR   CDD; cd00107; Knot1; 1.
DR   Gene3D; 3.30.30.10; -; 1.
DR   InterPro; IPR044062; LCN-type_CS_alpha_beta_dom.
DR   InterPro; IPR003614; Scorpion_toxin-like.
DR   InterPro; IPR036574; Scorpion_toxin-like_sf.
DR   InterPro; IPR018218; Scorpion_toxinL.
DR   InterPro; IPR002061; Scorpion_toxinL/defensin.
DR   Pfam; PF00537; Toxin_3; 1.
DR   PRINTS; PR00285; SCORPNTOXIN.
DR   SMART; SM00505; Knot1; 1.
DR   SUPFAM; SSF57095; SSF57095; 1.
DR   PROSITE; PS51863; LCN_CSAB; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cardiotoxin; Direct protein sequencing; Disulfide bond;
KW   Ion channel impairing toxin; Neurotoxin; Secreted; Signal; Toxin;
KW   Voltage-gated sodium channel impairing toxin.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000269|PubMed:8896191"
FT   CHAIN           20..83
FT                   /note="Alpha-like toxin BmK M1"
FT                   /evidence="ECO:0000269|PubMed:8896191"
FT                   /id="PRO_0000035236"
FT   PROPEP          84
FT                   /note="Removed by a carboxypeptidase"
FT                   /evidence="ECO:0000305"
FT                   /id="PRO_0000035237"
FT   DOMAIN          21..83
FT                   /note="LCN-type CS-alpha/beta"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01210"
FT   DISULFID        31..82
FT                   /evidence="ECO:0000269|PubMed:10493862,
FT                   ECO:0000269|PubMed:15321715, ECO:0000269|PubMed:16209876,
FT                   ECO:0000312|PDB:1DJT, ECO:0000312|PDB:1SN1,
FT                   ECO:0000312|PDB:1T7A, ECO:0000312|PDB:1T7B,
FT                   ECO:0000312|PDB:1T7E, ECO:0000312|PDB:1ZU3,
FT                   ECO:0000312|PDB:1ZUT, ECO:0000312|PDB:1ZVE,
FT                   ECO:0000312|PDB:1ZVG, ECO:0000312|PDB:1ZYV,
FT                   ECO:0000312|PDB:1ZYW"
FT   DISULFID        35..55
FT                   /evidence="ECO:0000269|PubMed:10493862,
FT                   ECO:0000269|PubMed:15321715, ECO:0000269|PubMed:16209876,
FT                   ECO:0000312|PDB:1DJT, ECO:0000312|PDB:1SN1,
FT                   ECO:0000312|PDB:1T7A, ECO:0000312|PDB:1T7B,
FT                   ECO:0000312|PDB:1T7E, ECO:0000312|PDB:1ZU3,
FT                   ECO:0000312|PDB:1ZUT, ECO:0000312|PDB:1ZVE,
FT                   ECO:0000312|PDB:1ZVG, ECO:0000312|PDB:1ZYV,
FT                   ECO:0000312|PDB:1ZYW"
FT   DISULFID        41..65
FT                   /evidence="ECO:0000269|PubMed:10493862,
FT                   ECO:0000269|PubMed:15321715, ECO:0000269|PubMed:16209876,
FT                   ECO:0000312|PDB:1DJT, ECO:0000312|PDB:1SN1,
FT                   ECO:0000312|PDB:1T7A, ECO:0000312|PDB:1T7B,
FT                   ECO:0000312|PDB:1T7E, ECO:0000312|PDB:1ZU3,
FT                   ECO:0000312|PDB:1ZUT, ECO:0000312|PDB:1ZVE,
FT                   ECO:0000312|PDB:1ZVG, ECO:0000312|PDB:1ZYV,
FT                   ECO:0000312|PDB:1ZYW"
FT   DISULFID        45..67
FT                   /evidence="ECO:0000269|PubMed:10493862,
FT                   ECO:0000269|PubMed:15321715, ECO:0000269|PubMed:16209876,
FT                   ECO:0000312|PDB:1DJT, ECO:0000312|PDB:1SN1,
FT                   ECO:0000312|PDB:1T7A, ECO:0000312|PDB:1T7B,
FT                   ECO:0000312|PDB:1T7E, ECO:0000312|PDB:1ZU3,
FT                   ECO:0000312|PDB:1ZUT, ECO:0000312|PDB:1ZVE,
FT                   ECO:0000312|PDB:1ZVG, ECO:0000312|PDB:1ZYV,
FT                   ECO:0000312|PDB:1ZYW"
FT   MUTAGEN         20..22
FT                   /note="Missing: 7.7-fold decrease in toxicity to mice, 3.2-
FT                   fold decrease in activity on Nav1.5/SCN5A, and 17.2-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         20
FT                   /note="Missing: 1.2-fold decrease in toxicity to mice, 8.6-
FT                   fold decrease in activity on Nav1.5/SCN5A, and 2.5-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         21
FT                   /note="R->A: 2.4-fold decrease in toxicity to mice, 15.2-
FT                   fold decrease in activity on Nav1.5/SCN5A, and 43.3-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         21
FT                   /note="R->E: 2.5-fold decrease in toxicity to mice, 1.6-
FT                   fold decrease in activity on Nav1.5/SCN5A, and 22.3-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         22
FT                   /note="D->A: 1.3-fold decrease in toxicity to mice, 16.8-
FT                   fold decrease in activity on Nav1.5/SCN5A, and 7.5-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         22
FT                   /note="D->N: 1.4-fold increase in toxicity to mice, 1.4-
FT                   fold increase in activity on Nav1.5/SCN5A, and 3.9-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         24
FT                   /note="Y->F: 25-fold decrease in toxicity to mice."
FT                   /evidence="ECO:0000269|PubMed:12692120,
FT                   ECO:0000269|PubMed:12705833"
FT   MUTAGEN         24
FT                   /note="Y->G: Complete loss of toxicity to mice, and 70-fold
FT                   decrease in the binding affinity for insect sodium
FT                   channels."
FT                   /evidence="ECO:0000269|PubMed:12692120,
FT                   ECO:0000269|PubMed:12705833"
FT   MUTAGEN         25
FT                   /note="I->G: >47-fold decrease in toxicity to mice, 2.4-
FT                   fold decrease in activity on Nav1.5/SCN5A, and 70-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         27..28
FT                   /note="KP->DS: 43.4-fold decrease in toxicity to mice, 170-
FT                   fold decrease in the binding affinity for insect sodium
FT                   channels."
FT   MUTAGEN         27
FT                   /note="K->D: 118-fold decrease in toxicity to mice, and
FT                   250-fold decrease in the binding affinity for insect sodium
FT                   channels."
FT                   /evidence="ECO:0000269|PubMed:12705833,
FT                   ECO:0000269|PubMed:15321715"
FT   MUTAGEN         28..29
FT                   /note="PH->NY: 3.3-fold increase in toxicity to mice, 7-
FT                   fold decrease in activity on Nav1.5/SCN5A, and 5.1-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         28
FT                   /note="P->N: 1.9-fold increase in toxicity to mice, 1.3-
FT                   fold increase in activity on Nav1.5/SCN5A, and 24.1-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         28
FT                   /note="P->S: 1.8-fold decrease in toxicity to mice, and
FT                   1.3-fold decrease in the binding affinity for insect sodium
FT                   channels."
FT                   /evidence="ECO:0000269|PubMed:12705833,
FT                   ECO:0000269|PubMed:15321715"
FT   MUTAGEN         29
FT                   /note="H->E: 1.7-fold decrease in toxicity to mice, and
FT                   0.8-fold decrease in the binding affinity for insect sodium
FT                   channels."
FT                   /evidence="ECO:0000269|PubMed:12705833"
FT   MUTAGEN         29
FT                   /note="H->Y: 2.2-fold decrease in toxicity to mice, 6.8-
FT                   fold increase in activity on Nav1.5/SCN5A, and 1.8-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         30
FT                   /note="N->A: Complete loss of toxicity to mice, 380-fold
FT                   decrease in the binding affinity for insect sodium
FT                   channels."
FT                   /evidence="ECO:0000269|PubMed:12705833"
FT   MUTAGEN         40
FT                   /note="Y->G: 1.9-fold decrease in toxicity to mice, and
FT                   1.4-fold decrease in the binding affinity for insect sodium
FT                   channels."
FT                   /evidence="ECO:0000269|PubMed:12705833"
FT   MUTAGEN         47
FT                   /note="K->E: 4.1-fold decrease in toxicity to mice, and 14-
FT                   fold decrease in the binding affinity for insect sodium
FT                   channels."
FT                   /evidence="ECO:0000269|PubMed:12705833"
FT   MUTAGEN         53
FT                   /note="G->A: 38-fold decrease in toxicity to mice, 11.2-
FT                   fold decrease in activity on Nav1.5/SCN5A, and 43.3-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         57
FT                   /note="W->G: More than 50-fold decrease in toxicity to
FT                   mice."
FT                   /evidence="ECO:0000269|PubMed:12692120"
FT   MUTAGEN         61
FT                   /note="Y->G: More than 50-fold decrease in toxicity to
FT                   mice."
FT                   /evidence="ECO:0000269|PubMed:12692120"
FT   MUTAGEN         62
FT                   /note="G->A: >47-fold decrease in toxicity to mice, loss of
FT                   activity on Nav1.5/SCN5A, and 56.7-fold decrease in
FT                   activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         70
FT                   /note="L->G: >47-fold decrease in toxicity to mice, loss of
FT                   activity on Nav1.5/SCN5A, and 233.3-fold decrease in
FT                   activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         71
FT                   /note="P->S: Not tested in mice, 1.2-fold decrease in
FT                   activity on Nav1.5/SCN5A, and 16.9-fold decrease in
FT                   activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         72
FT                   /note="D->A: 0.6-fold decrease in toxicity to mice, and
FT                   0.2-fold decrease in the binding affinity for insect sodium
FT                   channels."
FT                   /evidence="ECO:0000269|PubMed:12705833"
FT   MUTAGEN         76
FT                   /note="I->G: 1.1-fold decrease in toxicity to mice, loss of
FT                   activity on Nav1.5/SCN5A, and 2.5-fold decrease in activity
FT                   on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         77
FT                   /note="R->A: Complete loss of toxicity to mice, and
FT                   complete loss of affinity for insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:12705833"
FT   MUTAGEN         78
FT                   /note="V->G: 1.3-fold decrease in toxicity to mice, 2.6-
FT                   fold decrease in activity on Nav1.5/SCN5A, and 2.2-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         79
FT                   /note="P->A: 1.1-fold increase in toxicity to mice, 5.8-
FT                   fold decrease in activity on Nav1.5/SCN5A, and 20.4-fold
FT                   decrease in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         79
FT                   /note="P->G: 1.7-fold decrease in toxicity to mice, 1.3-
FT                   fold increase in activity on Nav1.5/SCN5A, and 1.7-fold
FT                   increase in activity on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         80
FT                   /note="G->A: 35-fold decrease in toxicity to mice, loss of
FT                   activity on Nav1.5/SCN5A, and 7.8-fold decrease in activity
FT                   on insect sodium channels."
FT                   /evidence="ECO:0000269|PubMed:15677695"
FT   MUTAGEN         81
FT                   /note="K->E: 71.4-fold decrease in toxicity to mice, and
FT                   170-fold decrease in the binding affinity for insect sodium
FT                   channels."
FT                   /evidence="ECO:0000269|PubMed:12705833"
FT   MUTAGEN         83
FT                   /note="H->A: 3.8-fold decrease in toxicity to mice, and
FT                   180-fold decrease in the binding affinity for insect sodium
FT                   channels."
FT                   /evidence="ECO:0000269|PubMed:12705833"
FT   MUTAGEN         83
FT                   /note="H->D: 43.9-fold decrease in toxicity to mice, and
FT                   96-fold decrease in the binding affinity for insect sodium
FT                   channels."
FT                   /evidence="ECO:0000269|PubMed:12705833"
FT   MUTAGEN         83
FT                   /note="H->K: 1.9-fold decrease in toxicity to mice, and
FT                   11.5-fold decrease in the binding affinity for insect
FT                   sodium channels."
FT                   /evidence="ECO:0000269|PubMed:12705833"
FT   CONFLICT        48
FT                   /note="N -> D (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   STRAND          21..27
FT                   /evidence="ECO:0007744|PDB:1DJT"
FT   TURN            28..30
FT                   /evidence="ECO:0007744|PDB:1DJT"
FT   HELIX           38..47
FT                   /evidence="ECO:0007744|PDB:1DJT"
FT   STRAND          51..59
FT                   /evidence="ECO:0007744|PDB:1DJT"
FT   STRAND          62..70
FT                   /evidence="ECO:0007744|PDB:1DJT"
SQ   SEQUENCE   84 AA;  9496 MW;  F8F14623AB2549A2 CRC64;
     MNYLVMISFA LLLMTGVESV RDAYIAKPHN CVYECARNEY CNDLCTKNGA KSGYCQWVGK
     YGNGCWCIEL PDNVPIRVPG KCHR
//
